BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 14506704)

  • 1. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
    Gabert J; Beillard E; van der Velden VH; Bi W; Grimwade D; Pallisgaard N; Barbany G; Cazzaniga G; Cayuela JM; Cavé H; Pane F; Aerts JL; De Micheli D; Thirion X; Pradel V; González M; Viehmann S; Malec M; Saglio G; van Dongen JJ
    Leukemia; 2003 Dec; 17(12):2318-57. PubMed ID: 14562125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative quantification of BCL2 mRNA for diagnostic usage needs stable uncontrolled genes as reference.
    Dwivedi N; Mondal S; P K S; T S; Sachdeva K; Bathula C; K V; K S N; Damodar S; Dhar SK; Das M
    PLoS One; 2020; 15(8):e0236338. PubMed ID: 32785215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.
    Del Principe MI; Buccisano F; Maurillo L; Sconocchia G; Cefalo M; Consalvo MI; Sarlo C; Conti C; De Santis G; De Bellis E; Di Veroli A; Palomba P; Attrotto C; Zizzari A; Paterno G; Voso MT; Del Poeta G; Lo-Coco F; Arcese W; Amadori S; Venditti A
    Mediterr J Hematol Infect Dis; 2016; 8(1):e2016052. PubMed ID: 27872732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia.
    Hirsch P; Zhang Y; Tang R; Joulin V; Boutroux H; Pronier E; Moatti H; Flandrin P; Marzac C; Bories D; Fava F; Mokrani H; Betems A; Lorre F; Favier R; Féger F; Mohty M; Douay L; Legrand O; Bilhou-Nabera C; Louache F; Delhommeau F
    Nat Commun; 2016 Aug; 7():12475. PubMed ID: 27534895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
    Kayser S; Walter RB; Stock W; Schlenk RF
    Curr Hematol Malig Rep; 2015 Jun; 10(2):132-44. PubMed ID: 25994952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines.
    Stolze B; Reinhart S; Bulllinger L; Fröhling S; Scholl C
    Sci Rep; 2015 Feb; 5():8535. PubMed ID: 25705018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease in acute myeloid leukaemia.
    Liu Yin JA
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of minimal residual disease in patients with t(15;17).
    Grimwade D
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):137-58. PubMed ID: 11987921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
    Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia.
    Super HG; Strissel PL; Sobulo OM; Burian D; Reshmi SC; Roe B; Zeleznik-Le NJ; Diaz MO; Rowley JD
    Genes Chromosomes Cancer; 1997 Oct; 20(2):185-95. PubMed ID: 9331569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
    Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
    Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
    Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
    Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia.
    Scholl C; Breitinger H; Schlenk RF; Döhner H; Fröhling S; Döhner K;
    Genes Chromosomes Cancer; 2003 Nov; 38(3):274-80. PubMed ID: 14506704
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.